Genus plc (LSE:GNS) launched a £60m share buyback after reporting a 35% rise in adjusted profit before tax to £100.2m for its 2026 financial year. The animal genetics group published its preliminary results on 10 September 2026.

What happened

Genus, a constituent of the FTSE All-Share index in the Pharmaceuticals and Biotechnology sector, released its preliminary results for the year to 30 June 2026 on 10 September 2026, followed by an earnings call the same day.

Adjusted profit before tax rose 35% to £100.2m for the 2026 financial year. Alongside the results, the company launched a £60m share buyback programme, returning surplus capital to shareholders.

The results followed the group's half-year figures, published in February 2026. The full-year announcement is the most recent detailed update from the company, with no further company-specific news of similar significance since.

Why it matters for investors

Crossing the £100m mark for adjusted profit before tax is a milestone for Genus, and a 35% increase represents a solid recovery in earnings. The group makes money by supplying genetics to pig and cattle farmers worldwide, through its PIC pork business and ABS dairy and beef business, and charges royalties linked to the value its genetics create for customers.

The buyback is a notable change in capital allocation. Genus has historically focused on reinvesting in R&D and on reducing debt, so committing £60m to share repurchases suggests management is confident about cash generation and the strength of the balance sheet.

A buyback also signals that the board sees value in the shares at current levels, although the main benefit for remaining shareholders is a smaller share count, which lifts earnings per share over time.

The longer-term investment case continues to rest on the company's PRRS-resistant pig, known as PRP. PRRS is a costly disease in pig farming, and Genus has spent years developing gene-edited animals resistant to it. Progress on regulatory approvals and commercial rollout in major pork-producing markets is a key driver of how investors value the business.

How the shares have performed

The combination of solid profit growth and a new buyback would usually be well received. However, investors in Genus tend to look beyond a single year's profits to the pace of growth in key markets, especially China and the US, and to the commercial outlook for PRP.

The buyback will provide steady demand for the shares while it runs, which may help support the price.

What to watch next

Genus's annual general meeting and any accompanying trading statement will be the next opportunity for an update on current trading in the 2027 financial year.

Investors will watch the progress of the £60m buyback, which will be reported through regular announcements. They will also look for news on PRP approvals and commercial agreements, which could open up significant new revenue streams.

Conditions in global pork and dairy markets, including farm profitability in China, the US and Europe, will influence demand for the group's genetics. The performance of the ABS business, which has been through a restructuring in recent years, will also be watched for signs of continued improvement.